PMC:7199903 / 586-903
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T6 | 174-182 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 102-103 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T8 | 183-188 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tests |
T9 | 231-232 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T4 | 142-149 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T8 | 52-57 | http://purl.obolibrary.org/obo/BFO_0000029 | denotes | sites |
T9 | 150-157 | http://purl.obolibrary.org/obo/BFO_0000019 | denotes | quality |
T10 | 312-317 | http://purl.obolibrary.org/obo/BFO_0000029 | denotes | sites |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T85 | 5-6 | -COMMA- | denotes | , |
T86 | 7-10 | CC | denotes | and |
T87 | 11-21 | VBD | denotes | determined |
T88 | 22-25 | DT | denotes | the |
T89 | 26-37 | NN | denotes | composition |
T90 | 38-40 | IN | denotes | of |
T91 | 41-44 | DT | denotes | the |
T92 | 45-51 | NN | denotes | glycan |
T93 | 52-57 | NNS | denotes | sites |
T94 | 58-60 | IN | denotes | by |
T95 | 61-65 | NN | denotes | mass |
T96 | 66-78 | NN | denotes | spectrometry |
T97 | 80-83 | DT | denotes | The |
T98 | 84-92 | NN | denotes | analysis |
T99 | 93-101 | VBZ | denotes | provides |
T100 | 102-103 | DT | denotes | a |
T101 | 104-113 | NN | denotes | benchmark |
T102 | 114-118 | WDT | denotes | that |
T103 | 119-122 | MD | denotes | can |
T104 | 123-125 | VB | denotes | be |
T105 | 126-130 | VBN | denotes | used |
T106 | 131-133 | TO | denotes | to |
T107 | 134-141 | VB | denotes | measure |
T108 | 142-149 | NN | denotes | antigen |
T109 | 150-157 | NN | denotes | quality |
T110 | 158-160 | IN | denotes | as |
T111 | 161-169 | NNS | denotes | vaccines |
T112 | 170-173 | CC | denotes | and |
T113 | 174-182 | NN | denotes | antibody |
T114 | 183-188 | NNS | denotes | tests |
T115 | 189-192 | VBP | denotes | are |
T116 | 193-202 | VBN | denotes | developed |
T117 | 204-211 | NN | denotes | Science |
T118 | 212-216 | DT | denotes | this |
T119 | 217-222 | NN | denotes | issue |
T120 | 223-224 | NN | denotes | p |
T121 | 226-229 | CD | denotes | 330 |
T122 | 231-232 | DT | denotes | A |
T123 | 233-237 | NN | denotes | mass |
T124 | 238-250 | NN | denotes | spectrometry |
T125 | 251-259 | NN | denotes | analysis |
T126 | 260-267 | VBZ | denotes | reveals |
T127 | 268-271 | DT | denotes | the |
T128 | 272-278 | NN | denotes | glycan |
T129 | 279-290 | NN | denotes | composition |
T130 | 291-293 | IN | denotes | at |
T131 | 294-297 | DT | denotes | all |
T132 | 298-311 | NN | denotes | glycosylation |
T133 | 312-317 | NNS | denotes | sites |
R92 | T89 | T88 | arg1Of | composition,the |
R93 | T89 | T90 | arg1Of | composition,of |
R94 | T93 | T90 | arg2Of | sites,of |
R95 | T93 | T91 | arg1Of | sites,the |
R96 | T93 | T92 | arg1Of | sites,glycan |
R97 | T89 | T94 | arg1Of | composition,by |
R98 | T96 | T94 | arg2Of | spectrometry,by |
R99 | T96 | T95 | arg1Of | spectrometry,mass |
R87 | T86 | T85 | arg1Of | and,"," |
R89 | T87 | T86 | arg2Of | determined,and |
R91 | T89 | T87 | arg2Of | composition,determined |
R100 | T98 | T97 | arg1Of | analysis,The |
R101 | T98 | T99 | arg1Of | analysis,provides |
R102 | T101 | T99 | arg2Of | benchmark,provides |
R103 | T101 | T100 | arg1Of | benchmark,a |
R104 | T101 | T102 | arg1Of | benchmark,that |
R105 | T101 | T103 | arg1Of | benchmark,can |
R106 | T105 | T103 | arg2Of | used,can |
R107 | T101 | T104 | arg1Of | benchmark,be |
R108 | T105 | T104 | arg2Of | used,be |
R109 | T101 | T105 | arg2Of | benchmark,used |
R110 | T107 | T105 | arg3Of | measure,used |
R111 | T107 | T106 | arg1Of | measure,to |
R112 | T101 | T107 | arg1Of | benchmark,measure |
R113 | T109 | T107 | arg2Of | quality,measure |
R114 | T109 | T108 | arg1Of | quality,antigen |
R115 | T107 | T110 | arg1Of | measure,as |
R116 | T116 | T110 | arg2Of | developed,as |
R117 | T111 | T112 | arg1Of | vaccines,and |
R118 | T114 | T112 | arg2Of | tests,and |
R119 | T114 | T113 | arg1Of | tests,antibody |
R120 | T112 | T115 | arg1Of | and,are |
R121 | T116 | T115 | arg2Of | developed,are |
R122 | T112 | T116 | arg2Of | and,developed |
R123 | T120 | T117 | arg1Of | p,Science |
R124 | T120 | T118 | arg1Of | p,this |
R125 | T120 | T119 | arg1Of | p,issue |
R126 | T125 | T122 | arg1Of | analysis,A |
R127 | T125 | T123 | arg1Of | analysis,mass |
R128 | T125 | T124 | arg1Of | analysis,spectrometry |
R129 | T125 | T126 | arg1Of | analysis,reveals |
R130 | T129 | T126 | arg2Of | composition,reveals |
R131 | T129 | T127 | arg1Of | composition,the |
R132 | T129 | T128 | arg1Of | composition,glycan |
R133 | T129 | T130 | arg1Of | composition,at |
R134 | T133 | T130 | arg2Of | sites,at |
R135 | T133 | T131 | arg1Of | sites,all |
R136 | T133 | T132 | arg1Of | sites,glycosylation |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T6 | 174-182 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 80-203 | Sentence | denotes | The analysis provides a benchmark that can be used to measure antigen quality as vaccines and antibody tests are developed. |
T8 | 204-225 | Sentence | denotes | Science this issue p. |
T9 | 226-229 | Sentence | denotes | 330 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
24 | 45-51 | Chemical | denotes | glycan | MESH:D011134 |
31 | 272-278 | Chemical | denotes | glycan | MESH:D011134 |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 298-311 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 298-311 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T2 | 298-311 | http://purl.obolibrary.org/obo/GO_0070085 | denotes | glycosylation |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T7 | 80-203 | Sentence | denotes | The analysis provides a benchmark that can be used to measure antigen quality as vaccines and antibody tests are developed. |
T8 | 204-225 | Sentence | denotes | Science this issue p. |
T9 | 226-229 | Sentence | denotes | 330 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
24 | 45-51 | Chemical | denotes | glycan | MESH:D011134 |
31 | 272-278 | Chemical | denotes | glycan | MESH:D011134 |